Entera Bio Appoints Geno Germano as Chairman of the Board
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 09 2026
0mins
Should l Buy ENTX?
Entera Bio (ENTX) announced that its Board of Directors has appointed Geno Germano as Chairman of the Board, effective February 4, 2026. Mr. Germano succeeds Gerald Lieberman, who is stepping down as Chairman. Germano is a pharmaceutical and life sciences executive with more than three decades of leadership experience spanning development, commercialization, and global operations. He held senior leadership roles at Pfizer (PFE), including as Group President of Pfizer's Global Innovative Pharmaceutical Business.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ENTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ENTX
Wall Street analysts forecast ENTX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.370
Low
10.00
Averages
10.00
High
10.00
Current: 1.370
Low
10.00
Averages
10.00
High
10.00
About ENTX
Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Entera Bio Shares Surge 15.71% After SEC Filing by Director
- Director Share Acquisition: Entera Bio's Director Steven D. Rubin purchased 5,000 ordinary shares at $1.49 each on February 12, totaling $7,450, increasing his direct holdings to 15,000 shares, indicating confidence in the company's future prospects.
- Stock Price Fluctuation: The stock surged 15.71% in after-hours trading to $1.62, following a 1.41% decline to $1.40 during regular trading, reflecting a positive market reaction to the SEC filing.
- Market Capitalization and Technical Indicators: Entera Bio has a market cap of $64.20 million, with a 52-week high of $3.22 and a low of $1, currently positioned about 18% above its 52-week low, indicating low volatility within its annual range.
- Analyst Ratings and Outlook: HC Wainwright & Co. reiterated a
See More
Entera Bio Board Members Increase Shareholdings
- Board Members Buy Shares: Entera Bio's Chairman Geno J. Germano purchased 20,000 shares at $1.49 each, while directors Steven D. Rubin, Haya Taitel, and Sean Ellis bought 10,000, 7,500, and 18,000 shares respectively at prices ranging from $1.20 to $1.48, indicating strong confidence in the company's future.
- Positive Market Reaction: Following the announcement of board member purchases, Entera Bio's stock surged 13% on Wednesday, reflecting optimistic market sentiment despite a 31% decline in stock price over the past year.
- CEO's Prior Purchases: This buying activity follows Entera's CEO Miranda Toledano's share purchases in December, demonstrating ongoing trust in the company's strategic direction, which may bolster investor confidence.
- Optimistic Market Sentiment: On Stocktwits, retail sentiment around ENTX stock remained in the 'bullish' territory with extremely high message volume, indicating strong expectations for the company's future, as users expressed optimism about the share purchases not being a waste of money.
See More
Entera Bio Plans Final EB613 Protocol Submission to FDA in Q1 2026
- FDA Submission Plan: Entera Bio plans to submit the final Phase 3 protocol for EB613 to the FDA in Q1 2026, following the FDA's broad qualification of bone mineral density as a regulatory endpoint for anti-osteoporosis drugs on December 19, 2025, which is expected to enhance the company's market position in osteoporosis.
- Clinical Study Progress: The Phase 1 bridging study for Next-Gen EB613, initiated in November 2025, is progressing on schedule with results expected by the end of Q1 2026, providing significant commercial and strategic advantages for the company.
- Accelerated Treatment Program: Entera plans to accelerate its hypoparathyroidism treatment program in 2026 based on robust preclinical PK/PD data for a proprietary long-acting PTH analog announced in late December 2025, aiming to meet the urgent market demand for new therapies.
- Strategic Partnership Discussions: The company is actively engaging in strategic partnership discussions to optimize the development and commercialization pathway for its first-in-class oral peptide programs, indicating a strong commitment to investment and innovation in areas of unmet medical needs.
See More
China SXT Pharmaceuticals (SXTC) Closes $10 Million Offering, Stock Rises 17.4%
- Successful Financing: China SXT Pharmaceuticals, Inc. announced the closing of a registered direct offering valued at approximately $10 million, selling 66,666,666 Class A ordinary shares at $0.15 each to a single investor, thereby strengthening its balance sheet and boosting investor confidence.
- Financial Guidance: TG Therapeutics reported preliminary U.S. net product revenue for its multiple sclerosis therapy BRIUMVI for Q4 and full-year 2025, with shares rising 6.99% to $29.82, showcasing the company's growth potential.
- FDA Review Progress: Argenx SE's supplemental Biologics License Application for VYVGART, aimed at treating adults with acetylcholine receptor antibody seronegative generalized myasthenia gravis, has been accepted for priority review by the FDA, with a target action date of May 10, 2026, indicating potential for expanded indications.
- Market Trends: Cosmos Health Inc. saw its stock rise 6.09% to $0.4961 despite no specific news, reflecting speculative interest and momentum trading in the micro-cap healthcare sector.
See More
Entera Receives FDA Qualification of Total Hip BMD as a Key Endpoint for Osteoporosis Drug Development
- FDA Qualification: Entera Bio has received broad FDA qualification for total hip bone mineral density (BMD) as a validated regulatory endpoint, which will simplify the pathway for its NDA submission for EB613, potentially accelerating drug development timelines.
- Market Demand: With over 200 million women globally estimated to have osteoporosis and largely undertreated, this regulatory reform by the FDA presents Entera with a significant opportunity to address this unmet medical need, enhancing its competitive position in the market.
- Clinical Trial Innovation: EB613, as the first oral once-daily anabolic treatment, has successfully met all biomarker and BMD endpoints in a Phase 2 trial involving 161 patients, demonstrating its potential to lower fracture risk and possibly transform the treatment landscape for osteoporosis.
- Strategic Vision: Entera's CEO emphasized the company's commitment to improving the quality of life for osteoporosis patients through innovative therapies, with FDA support likely facilitating broader market access by 2025, furthering the democratization of osteoporosis treatment globally.
See More
Entera Bio Reports Financial Results and Business Developments for Q3 2025
FDA Agreement on EB613: The FDA has approved Entera Bio's proposal for a Phase 3 study of EB613, focusing on bone mineral density (BMD) as the primary endpoint, which aims to support a New Drug Application for the first oral treatment for osteoporosis in post-menopausal women.
Phase 2 Data Highlights: Recent presentations at major medical conferences showcased EB613's significant efficacy in increasing both trabecular and cortical bone indices in younger post-menopausal women, indicating rapid bone strengthening comparable to existing injectable treatments.
Next-Generation EB613 and Other Programs: Entera is on track to initiate a Phase 1 trial for a next-generation version of EB613 in late 2025, while also advancing oral therapies for short bowel syndrome and obesity in collaboration with OPKO Health.
Financial Overview: For the quarter ending September 30, 2025, Entera reported a net loss of $3.2 million, with cash reserves expected to support operations through mid-2026, reflecting ongoing investments in research and development for its innovative oral peptide therapies.
See More
Entera Bio Shares Surge 15.71% After SEC Filing by Director
- Director Share Acquisition: Entera Bio's Director Steven D. Rubin purchased 5,000 ordinary shares at $1.49 each on February 12, totaling $7,450, increasing his direct holdings to 15,000 shares, indicating confidence in the company's future prospects.
- Stock Price Fluctuation: The stock surged 15.71% in after-hours trading to $1.62, following a 1.41% decline to $1.40 during regular trading, reflecting a positive market reaction to the SEC filing.
- Market Capitalization and Technical Indicators: Entera Bio has a market cap of $64.20 million, with a 52-week high of $3.22 and a low of $1, currently positioned about 18% above its 52-week low, indicating low volatility within its annual range.
- Analyst Ratings and Outlook: HC Wainwright & Co. reiterated a
See More
Entera Bio Board Members Increase Shareholdings
- Board Members Buy Shares: Entera Bio's Chairman Geno J. Germano purchased 20,000 shares at $1.49 each, while directors Steven D. Rubin, Haya Taitel, and Sean Ellis bought 10,000, 7,500, and 18,000 shares respectively at prices ranging from $1.20 to $1.48, indicating strong confidence in the company's future.
- Positive Market Reaction: Following the announcement of board member purchases, Entera Bio's stock surged 13% on Wednesday, reflecting optimistic market sentiment despite a 31% decline in stock price over the past year.
- CEO's Prior Purchases: This buying activity follows Entera's CEO Miranda Toledano's share purchases in December, demonstrating ongoing trust in the company's strategic direction, which may bolster investor confidence.
- Optimistic Market Sentiment: On Stocktwits, retail sentiment around ENTX stock remained in the 'bullish' territory with extremely high message volume, indicating strong expectations for the company's future, as users expressed optimism about the share purchases not being a waste of money.
See More
Entera Bio Plans Final EB613 Protocol Submission to FDA in Q1 2026
- FDA Submission Plan: Entera Bio plans to submit the final Phase 3 protocol for EB613 to the FDA in Q1 2026, following the FDA's broad qualification of bone mineral density as a regulatory endpoint for anti-osteoporosis drugs on December 19, 2025, which is expected to enhance the company's market position in osteoporosis.
- Clinical Study Progress: The Phase 1 bridging study for Next-Gen EB613, initiated in November 2025, is progressing on schedule with results expected by the end of Q1 2026, providing significant commercial and strategic advantages for the company.
- Accelerated Treatment Program: Entera plans to accelerate its hypoparathyroidism treatment program in 2026 based on robust preclinical PK/PD data for a proprietary long-acting PTH analog announced in late December 2025, aiming to meet the urgent market demand for new therapies.
- Strategic Partnership Discussions: The company is actively engaging in strategic partnership discussions to optimize the development and commercialization pathway for its first-in-class oral peptide programs, indicating a strong commitment to investment and innovation in areas of unmet medical needs.
See More
China SXT Pharmaceuticals (SXTC) Closes $10 Million Offering, Stock Rises 17.4%
- Successful Financing: China SXT Pharmaceuticals, Inc. announced the closing of a registered direct offering valued at approximately $10 million, selling 66,666,666 Class A ordinary shares at $0.15 each to a single investor, thereby strengthening its balance sheet and boosting investor confidence.
- Financial Guidance: TG Therapeutics reported preliminary U.S. net product revenue for its multiple sclerosis therapy BRIUMVI for Q4 and full-year 2025, with shares rising 6.99% to $29.82, showcasing the company's growth potential.
- FDA Review Progress: Argenx SE's supplemental Biologics License Application for VYVGART, aimed at treating adults with acetylcholine receptor antibody seronegative generalized myasthenia gravis, has been accepted for priority review by the FDA, with a target action date of May 10, 2026, indicating potential for expanded indications.
- Market Trends: Cosmos Health Inc. saw its stock rise 6.09% to $0.4961 despite no specific news, reflecting speculative interest and momentum trading in the micro-cap healthcare sector.
See More
Entera Receives FDA Qualification of Total Hip BMD as a Key Endpoint for Osteoporosis Drug Development
- FDA Qualification: Entera Bio has received broad FDA qualification for total hip bone mineral density (BMD) as a validated regulatory endpoint, which will simplify the pathway for its NDA submission for EB613, potentially accelerating drug development timelines.
- Market Demand: With over 200 million women globally estimated to have osteoporosis and largely undertreated, this regulatory reform by the FDA presents Entera with a significant opportunity to address this unmet medical need, enhancing its competitive position in the market.
- Clinical Trial Innovation: EB613, as the first oral once-daily anabolic treatment, has successfully met all biomarker and BMD endpoints in a Phase 2 trial involving 161 patients, demonstrating its potential to lower fracture risk and possibly transform the treatment landscape for osteoporosis.
- Strategic Vision: Entera's CEO emphasized the company's commitment to improving the quality of life for osteoporosis patients through innovative therapies, with FDA support likely facilitating broader market access by 2025, furthering the democratization of osteoporosis treatment globally.
See More
Entera Bio Reports Financial Results and Business Developments for Q3 2025
FDA Agreement on EB613: The FDA has approved Entera Bio's proposal for a Phase 3 study of EB613, focusing on bone mineral density (BMD) as the primary endpoint, which aims to support a New Drug Application for the first oral treatment for osteoporosis in post-menopausal women.
Phase 2 Data Highlights: Recent presentations at major medical conferences showcased EB613's significant efficacy in increasing both trabecular and cortical bone indices in younger post-menopausal women, indicating rapid bone strengthening comparable to existing injectable treatments.
Next-Generation EB613 and Other Programs: Entera is on track to initiate a Phase 1 trial for a next-generation version of EB613 in late 2025, while also advancing oral therapies for short bowel syndrome and obesity in collaboration with OPKO Health.
Financial Overview: For the quarter ending September 30, 2025, Entera reported a net loss of $3.2 million, with cash reserves expected to support operations through mid-2026, reflecting ongoing investments in research and development for its innovative oral peptide therapies.
See More
